Literature DB >> 21792543

Update on the management of Crohn's disease.

Anna M Buchner1, Wojciech Blonski, Gary R Lichtenstein.   

Abstract

Crohn's disease (CD) is a chronic inflammatory disorder characterized by focal, asymmetric, transmural inflammation of any part of the luminal gastrointestinal tract of uncertain etiology and an unpredictable course. The available treatment options include aminosalicylates, budesonide and systemic corticosteroids, antibiotics, immunomodulators,methotrexate and anti-TNF agents. This review discusses recent developments in the treatment of CD and provides a comprehensive update on management of patients with CD based on the data from randomized controlled trials.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21792543     DOI： 10.1007/s11894-011-0220-x

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN： 1522-8037


  71 in total

1.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management.

Authors:  A Dignass; G Van Assche; J O Lindsay; M Lémann; J Söderholm; J F Colombel; S Danese; A D'Hoore; M Gassull; F Gomollón; D W Hommes; P Michetti; C O'Morain; T Oresland; A Windsor; E F Stange; S P L Travis
Journal:  J Crohns Colitis       Date:  2010-01-15       Impact factor: 9.071

Review 2.  A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn's disease.

Authors:  Roja Rahimi; Shekoufeh Nikfar; Ali Rezaie; Mohammad Abdollahi
Journal:  Clin Ther       Date:  2006-12       Impact factor: 3.393

3.  Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine.

Authors:  José-Tomás Navarro; Josep-Maria Ribera; José-Luis Mate; Isabel Granada; Jordi Juncà; Montserrat Batlle; Fuensanta Millá; Evarist Feliu
Journal:  Leuk Lymphoma       Date:  2003-03

4.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

Authors:  A Kandiel; A G Fraser; B I Korelitz; C Brensinger; J D Lewis
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

Review 5.  Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease.

Authors:  Morris Gordon; Khimara Naidoo; Adrian G Thomas; Anthony K Akobeng
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

6.  Kinetics of 5-aminosalicylic acid after jejunal instillation in man.

Authors:  O Haagen Nielsen; S Bondesen
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

7.  Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology.

Authors:  J M Kremer; G S Alarcón; R W Lightfoot; R F Willkens; D E Furst; H J Williams; P B Dent; M E Weinblatt
Journal:  Arthritis Rheum       Date:  1994-03

8.  Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease.

Authors:  W R Connell; M A Kamm; M Dickson; A M Balkwill; J K Ritchie; J E Lennard-Jones
Journal:  Lancet       Date:  1994-05-21       Impact factor: 79.321

9.  Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

Authors:  J P Gendre; J Y Mary; C Florent; R Modigliani; J F Colombel; J C Soulé; J P Galmiche; E Lerebours; L Descos; J M Viteau
Journal:  Gastroenterology       Date:  1993-02       Impact factor: 22.682

Review 10.  Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.

Authors:  Eliza Prefontaine; Lloyd R Sutherland; John K Macdonald; Monica Cepoiu
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21
View more
  7 in total

1.  Helicobacter pylori and Crohn's disease: a retrospective single-center study from China.

Authors:  Zun Xiang; Yi-Peng Chen; Yue-Fang Ye; Kui-Fen Ma; Shao-Hua Chen; Lin Zheng; Yi-Da Yang; Xi Jin
Journal:  World J Gastroenterol       Date:  2013-07-28       Impact factor: 5.742

Review 2.  Helicobacter pylori infection and inflammatory bowel disease: is there a link?

Authors:  Konstantinos Papamichael; Panagiotis Konstantopoulos; Gerassimos J Mantzaris
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

Review 3.  Changes of the cytokine profile in inflammatory bowel diseases.

Authors:  Györgyi Műzes; Béla Molnár; Zsolt Tulassay; Ferenc Sipos
Journal:  World J Gastroenterol       Date:  2012-11-07       Impact factor: 5.742

Review 4.  Personalized medicine using DNA biomarkers: a review.

Authors:  Andreas Ziegler; Armin Koch; Katja Krockenberger; Anika Grosshennig
Journal:  Hum Genet       Date:  2012-07-01       Impact factor: 4.132

5.  A phase II study of laquinimod in Crohn's disease.

Authors:  Geert D'Haens; William J Sandborn; Jean Frederic Colombel; Paul Rutgeerts; Kurt Brown; Hadas Barkay; Anat Sakov; Asi Haviv; Brian G Feagan
Journal:  Gut       Date:  2014-10-03       Impact factor: 23.059

Review 6.  A guide to prepare patients with inflammatory bowel diseases for anti-TNF-α therapy.

Authors:  Júlio Maria Fonseca Chebli; Pedro Duarte Gaburri; Liliana Andrade Chebli; Tarsila Campanha da Rocha Ribeiro; André Luiz Tavares Pinto; Orlando Ambrogini Júnior; Adérson Omar Mourão Cintra Damião
Journal:  Med Sci Monit       Date:  2014-03-26

Review 7.  Efficacy and safety of selective glucocorticoid receptor modulators in comparison to glucocorticoids in arthritis, a systematic review.

Authors:  M Safy; M J H de Hair; J W G Jacobs; F Buttgereit; M C Kraan; J M van Laar
Journal:  PLoS One       Date:  2017-12-21       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.